In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Prognostic impact of SYNTAX Score in patients with myocardial infarction with multivessel coronary artery disease and cardiogenic shock: insight from the CULPRIT-SHOCK Trial
Topic : interventional cardiology and cardiovascular surgery
Sub-topic : Coronary Intervention
Session type : Advances in Science
Authors : P Guedeney (Paris,FR), O Barthelemy (Paris,FR), M Zeitouni (Paris,FR), M Hauguel-Moreau (Paris,FR), G Hage (Paris,FR), P Overtchouk (Paris,FR), S Rouanet (Levallois Perret,FR), E Vicaut (paris,FR), S De Waha-Thiele (Leipzig,DE), U Zeymer (Ludwigshafen,DE), M Sandri (Leipzig,DE), I Akin (Leipzig,DE), S Desch (Leipzig,DE), H Thiele (Leipzig,DE), G Montalescot (Paris,FR)
P Guedeney1
,
O Barthelemy1
,
M Zeitouni1
,
M Hauguel-Moreau1
,
G Hage1
,
P Overtchouk1
,
S Rouanet2
,
E Vicaut3
,
S De Waha-Thiele4
,
U Zeymer5
,
M Sandri4
,
I Akin4
,
S Desch4
,
H Thiele4
,
G Montalescot1
,
1Hospital Pitie-Salpetriere - Paris - France
,
2StatEthic, Statistician unit - Levallois Perret - France
,
3Action study group, Unité de recherche Clinique, Hôpital Lariboisière - paris - France
,
4Heart Center of Leipzig, Cardiology - Leipzig - Germany
,
5Stiftung Institut fǬr Herzinfarktforschung, Cardiology - Ludwigshafen - Germany
,
On behalf: CULPRIT SHOCK investigator
Citation:
Background: The majority of patients presenting with myocardial infarction (MI) and cardiogenic shock (CS) have multivessel coronary artery disease. The prognosis impact of the SYNTAX score (SS) in this setting remains unknown.
Purpose: To evaluate the prognosis value of the SS in this high-risk population undergoing percutaneous coronary intervention (PCI)
Methods: The CULPRIT-SHOCK trial was an international, open-label trial, where patients presenting with MI and multivessel disease complicated by CS were randomized to a culprit-lesion-only or an immediate multivessel PCI strategy. Pre-PCI SS was assessed by a central core laboratory and patients were categorized as low SS (SS =22), intermediate SS (22-32) and high SS (SS>32). Adjudicated endpoints of interest were the risks of all-cause death or renal replacement therapy at 30 days and all-cause death at 1 year. Associations between SYNTAX score and outcomes were assessed using multivariate logistic regression.
Results: SS was available in 632 patients, of whom 265 (41.9%), 211 (33.4%) and 156 (24.7%) presented with low, intermediate and high SS, respectively. Patients with higher SS were older, with more frequent peripheral artery disease, less current smoking, lower creatinine clearance, and higher use of catecholamine. A stepwise increase in the incidence of adverse events transitioning from low to intermediate and high SS was observed with the 30-day risk of death or renal replacement therapy as well as the 1-year risk of all-cause death (p for trend <0.001, for all). After multiple adjustment, intermediate and high SS remained strongly associated with 30-day risk of death and renal replacement therapy and 1-year risk of all-cause death (Figure). There was no significant interaction between SYNTAX score and the coronary revascularization strategy for all endpoints.
Conclusion: In patients presenting with acute MI, multivessel disease and CS, the SYNTAX score was strongly associated to 30-day and 1-year mortality
In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease
